Millions of vaccine records scoured for rare side effects

NCT ID NCT06743334

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study uses a nationwide health database in South Korea to track the safety of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in over 14 million people. Researchers will look for rare adverse events and severe COVID-19 outcomes after vaccination. The goal is to better understand the vaccine's real-world safety across different age groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tozinameran (BNT162b2) COVID-19 vaccine
What this could lead to: If successful, this study could provide a clearer picture of the vaccine's real-world safety profile, helping to guide public health decisions.
What could go wrong: This is an observational study using existing data, so it cannot prove cause and effect. Results may be influenced by factors like underlying health conditions or reporting biases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS COV-2

Contacts and locations

Show contact details

Locations

Pfizer

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.